TALK TO OUR ENQUIRY TEAM: +44 (0)203 941 2000


The Important Role of Genomics and Pharmacogenetics to enhance Mental Health Treatment

Research into some mental health conditions has been aided by the incredible progress of genomics (the study of genes and their functions through genetic testing). Genomics has started to have a significant impact on many areas of clinical care including mental health management.

Take conditions such as anxiety disorder and chronic depression; when previously treating mental health issues like these, drug dosage was based on empirical (or observational) evidence.  With this type of approach, it is not always possible to predict a patient’s probability of response, the risk of side effects and the dosage needed for a drug to be effective. This means that patients did not often respond well to their prescribed treatment, or they experienced unpleasant side effects (that often lead to discontinuation of the medication).

Well-established studies of pharmacogenetics (how genes affect a patient’s response to drugs) have demonstrated that individuals have different ways to metabolise medications according to their genetic make-up.

Metabolism is aided by enzymes in the body. The most important cytochromes (enzymes in the body) with regards to metabolism and mental health conditions are CYP1C19 and CYP2D6. Many antidepressants often used in mental health treatment (including fluoxetine – Prozac and Sertraline) are metabolised by CYP2D6. Individuals that have this overactive cytochrome might need to adjust their medication dosage in order to be able to respond to treatment in the best possible way.

Which type of metaboliser are you?

Much of the population are defined as ‘normal’ or ‘extensive’ metabolisers, that is, they can metabolise a drug in a ‘normal’ way because the two genes that code for the molecules involved in drug metabolism –the cytochromes – are present and active in those individuals.

Other people are defined as ‘intermediate metabolisers’. They can metabolise a drug, but they do so in a less efficient way than ‘normal’ because only one required gene is active rather than two.

Then some individuals either metabolise drugs extremely rapidly (‘ultra-rapid metabolisers’), or, they don’t have the ability to metabolise some drugs at all (‘poor metabolisers’).

Ultra-rapid metabolisers often need a significantly higher dose of medication, or a different medication altogether (one that is not metabolised by the same molecule), as a standard dose of medication is not effective for them.

While poor metabolisers do not metabolise medication, which means that even standard doses of medication, might be toxic to them.

Different populations have diverse prevalence of ultra-rapid or poor metabolisers. People from the Middle East, for instance, have a significantly higher percentage of fast metabolisers compared to the Caucasian population.

This means that this population is most likely to need a genetic screening of the cytochromes compared to the Caucasian population.

How does metabolic data help?

Knowing the metabolic status of a patient is helpful – not just to optimise treatment – but also to avoid unnecessary side effects (which can be extremely severe). One drug where the importance of a patient’s metabolic status is frequently referenced is codeine. Once this drug has entered the system, it converts into morphine. Individuals who are ultra-rapid metabolisers will convert codeine into morphine at a phenomenal speed and therefore, even a dosage that is considered safe in the majority of population, can be toxic or even lethal to these types.

For this reason, the best health care providers have incorporated genetic testing into their routine clinical practice for patients with mental health conditions.  This type of personalised approach to patient research helps practitioners take a more individual stance when treating mental health concerns.

Dr Antonio Metastasio – Consultant Ps
Consultant Psychiatrist

Dr Metastasio qualified from the University of Perugia (Italy) in 2000. He then trained as Geriatrician in Italy. Subsequently, he moved to the UK and completed his postgraduate training in Adult Psychiatry (with an endorsement in Addiction and in Rehabilitation Psychiatry) at Cambridge in 2012. Dr Metastasio also completed his MSc in Addiction Biology at the Institute of Psychiatry, King’s College London in 2012. He was appointed Consultant Psychiatrist the same year.

To find out how BREVIN can help with it's approach to treating mental illness, dealing with the individual on a one to one level in the luxury of their home surroundings, please contact us for more information.

Click here...

Talk to us on+44 (0)203 941 2000

Other mental health related articles

Mental Health Briefings

Home Care is the option to psychiatric hospital for mental health patients

October 23, 2018
A proportion of patients with mental illness become too unwell for outpatient treatment with their psychiatrist or therapist. Their condition graduates to a higher level of severity and/ or an elevated risk of further deterioration. The treatment needs of these patients involve four key requirements
Read more
Mental Health Briefings

The importance of mental health in the workplace

August 23, 2018
Mental Health is big news. No longer swept under society’s plush carpet, it has been discussed in the House of Lords, across global media and perhaps most importantly, in the workplace.
Read more
Mental Health Briefings

How to help support a Friend or Family Member with a Mental Illness

October 19, 2018
When a person experiences mental illness, it affects those around them also. If you haven’t experienced mental illness yourself, it can be complicated initiating help to someone who is suffering. Frequently our patients are frustrated by their condition, describing the illness as being ‘invisible’
Read more

Please contact us on 0203 941 2000 to speak to a member of our enquiry team:

At BREVIN, discretion and privacy are cornerstones of our service. We would love to keep you up to date with you by post, email and other electronic means with information about our service, news about BREVIN and engaging articles about mental health. Please be reassured we'll treat your information with the utmost care and will never pass it to other parties.

Oops! Something went wrong while submitting the form.

Here are some useful considerations when enquiring about our service:

  • We treat adults over the age of 18
  • We are regulated by the CQC
  • Our treatment services are available in London and the surrounding areas
  • We can work alongside your existing clinical team
  • We do not need a referral
  • We can work with your existing GP or appoint one for you
  • We do not work with patients whose level of severity is mild or moderate without a significant level of dysfunction who are likely to improve with treatment under a psychiatrist or therapy alone;
BREVIN Home Care Ltd, 52 Grosvenor Gardens, Belgravia, London, SW1W 0AU
Brevin Homecare Ltd trading as BREVIN is regulated by The Care Quality Commission. ©BREVIN 2018. All rights reserved.